The acquisition is subject to rapid tests for viral antigen indications and viral antibody assays for units of HusLab and ISLAB.

The acquisition is divided into subdivisions:

1. Quick TBEV-IGM (HUSLAB) and Pika PUV-IGM tests (HUSLAB and ISLAB)

2. Rota- and adenovirus tests on antigen stool (HUSLAB and ISLAB)

3. RS virus test antigen test on airway sample (HUSLAB)

4. Adenovirus antigen test on eye samples (HUSLAB and ISLAB)

5. Mononucleosis test (HUSLAB and ISLAB)

All subdivisions are compared separately, meaning the vendor does not need to provide a test for all the subdivisions mentioned. The bidder may make up to one offer for each subdivision. Intra-subdivision offers are not accepted. Setting parallel bids is not allowed.

The test price shall include the test reagents, controls, operational training, delivery costs and product support required to conduct the test.

The acquisition is contracted (on a sub-region basis) for a contract period of two (2) years. The contract may (on a sub-region basis) be extended for two one-year option periods (1+1).

The contract period begins when both sides have signed an agreement.

The object of the acquisition and its requirements are described in detail in the call for tender and its annexes.

The acquisition is subject to rapid tests for the determination of Paumala-virus IgM antibodies from a serum sample for HUSLab and ISLAB, and for the determination of TBEV-IgM antibodies from serum and liquid samples for HUSLab. The tests to be acquired are immunochromatographic vieri, or POC (point-of-care) tests. The results of the tests should be readable on the ReasCan+ reading device used in HUSLab.

The Subscriber will select one (1) supplier with whom it will contract.

The acquisition is subject to a quick test for rat and adenoviruses antigen demonstration from a fecal sample for HUSLab and ISLAB. The test to be obtained is an immunochromatographic vieri, or POC (point-of-care) test, which does not require a separate device excluding pipettes.

The subscriber selects two (2) vendors with which it enters into a framework agreement. On placing orders, see the entry 'Basics of decision'.

The acquisition is subject to an antigen detection rapid test to demonstrate RSV infection from airway samples to HUSLAB. The test to be obtained is an immunochromatographic vieri, or POC (point-of-care) test, which does not require a separate device excluding pipettes.

The Subscriber will select one (1) supplier with whom it will contract.

The acquisition is subject to a quick test for HUSLAB and ISLAB for the demonstration of the adenovirus antigen taken directly from the eye. The test to be obtained is an immunochromatographic vieri, or POC (point-of-care) test, which does not require a separate device excluding pipettes.

The Subscriber will select one (1) supplier with whom it will contract.

The acquisition is subject to a quick test for the qualitative assignment of heterophilic IgM antibodies found in connection with EBV-induced mononucleosis (IM) from serum to HUSLab and ISLAB. The procurement test is an immunochromatographic vieri, or POC (point-of-care) test, which does not require a separate device excluding pipettes.

The subscriber selects two (2) vendors with which it enters into a framework agreement. On placing orders, see the entry 'Basics of decision'.